**Core Concept**
Osteogenesis imperfecta is a genetic disorder characterized by fragile bones, often resulting from a defect in the production of collagen, a key structural protein in bone. The biochemical abnormality underlying this condition involves a mutation in the COL1A1 or COL1A2 gene, which encodes for the alpha-1 or alpha-2 chains of type I collagen.

**Why the Correct Answer is Right**
The correct answer is related to the impaired post-translational modification of collagen, specifically the reduced activity of prolyl hydroxylase (P4H), an enzyme responsible for hydroxylating proline residues in collagen. This modification is crucial for the proper folding and cross-linking of collagen molecules, leading to the formation of stable bone tissue. In osteogenesis imperfecta, the mutation affects the structure or function of the P4H enzyme, resulting in the accumulation of unmodified collagen molecules that are prone to degradation.

**Why Each Wrong Option is Incorrect**
**Option A:** While osteomalacia is a condition characterized by softening of the bones due to impaired mineralization, it is not directly related to the biochemical abnormality in osteogenesis imperfecta.

**Option B:** Glycosylation is an important post-translational modification that affects many proteins, but it is not directly involved in the pathogenesis of osteogenesis imperfecta.

**Option C:** Pyridinoline cross-links are indeed important for the stability of collagen, but the biochemical abnormality in osteogenesis imperfecta is related to the impaired formation of these cross-links, rather than their presence.

**Clinical Pearl / High-Yield Fact**
Osteogenesis imperfecta is often associated with blue sclerae, a characteristic feature of the condition that results from the transparency of the scleral collagen.

**Correct Answer:** C.